We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This is the first study to evaluate the prevalence of SARS-CoV-2 testing and COVID-19 in inflammatory bowel disease (IBD) patients in a US cohort. The prevalence of IBD among patients undergoing SARS-CoV-2 testing is 1.2%, which is comparable to the prevalence of IBD (1.3%) in the US adult population. A COVID-19 positivity rate of 3% in IBD patients is comparable to the population-weighted prevalence of SARS-CoV-2 positive serology in Santa Clara county, at 2.8%.
These data suggest that patients with IBD are not disproportionately being tested or diagnosed with SARS-CoV-2 compared with the background population in northern California.
– Omar Khan, MD
This abstract is available on the publisher's site.
Coronavirus disease 2019 (COVID-19), caused by the novel betacoronavirus SARSCoV-2, is an unprecedented global pandemic.1 Susceptibility to COVID-19 is a concern among patients with inflammatory bowel disease (IBD) who are at increased risk of infection due to immunosuppressive therapy. The receptor angiotensin converting enzyme 2 (ACE2), which mediates SARS-CoV-2 entry into cells, is upregulated in IBD2 and may therefore increase host susceptibility. International cohorts have reported no increased risk of COVID-19 in patients with IBD.3,4 However, these studies do not report the prevalence of SARS-CoV-2 testing and COVID-19 in IBD patients. Our institution was among the first to initiate large-scale SARS-CoV-2 RNA testing in northern California. We characterized the prevalence and clinical predictors of COVID-19 in patients with IBD.